Effect of supplementation with berberine on dyslipidemias in humans: A systematic review
Keywords:Berberine; Coptis Chinenses; Dislipidemia.
Objective: to describe in a systematic review, the outcomes of clinical trials related to supplementation with berberine and dyslipidemia in humans. Methodology: The search for the articles was carried out in the Pubmed, ScienceDirect, Cochrane and Lilacs databases. The PICO strategy (patient, intervention, comparison and outcomes) was used to define the guiding question for this review. The terms “Coptis chinensis OR Berberine” AND “Dyslipidemia OR Dyslipoproteinemias” were used for the bibliographical survey. Included in this systematic review were randomized, double-blind, placebo controlled clinical trials, published in English, with no year limit of publication, which evaluated the effect of supplementation with berberine on the influence on lipid profiles in humans with dyslipidemia, without gender restriction, age and ethnicity. Results: After the screening process, removal of duplicate articles and analysis of the inclusion criteria, 10 articles were identified as eligible for this systematic review. Discussion: most of the included clinical trials found a reduction in the levels of total cholesterol, triglycerides and LDL. The outcomes of all studies were similar, indicating that berberine and its respective bioactive compounds have potential in the treatment of dyslipidemia. Conclusion: The results of this systematic review provide evidence of the benefits of berberine supplementation on the lipid profile, total cholesterol, triglycerides and the reduction of LDL levels in dyslipidemic individuals. However, further intervention studies are needed to extrapolate the results of this study in different populations, as well as to standardize doses of berberine extract for supplementation.
Amorim, M. F. D., Diniz, M. F. F. M., Araújo, M. S. T., Pita, J. C. L. R.; Dantas, J. G., Ramalho, J. A., Xavier, A. L., Palomaro, T. V., Júnior, N. L. B. (2007).
The controvertible role of kava (Piper methysticum G. Foster) an anxiolytic herb, on toxic hepatitis. Revista Brasileira de Farmacognosia, 17(3), 448-454.
Affuso, F., Mercurio, V., Fazio, V., Fazio, S. (2010). Cardiovascular and metabolic effects of Berberine. World Journal of Cardiology, 2(4), 71-77.
Cicero, A., Rovati, L., & Setnikar, I. (2007). Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering Agents. Arzneimittelforschung, 57(01), 26–30.
Cicero, A., Ertek, S. (2009). Berberine: metabolic and cardiovascular effects in preclinical and clinical trials. Nutrition and Dietary Supplements, 1,1-10.
Derosa, G., Romano, D., D'angelo, A., Maffioli, P. (2015). Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. Phytomedicine, 22(2), 231-237.
Dong, H., Zhao, Y., Zhao, Li., Lu, F. (2013). The Effects of Berberine on Blood Lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Medica, 79(6), 437-446.
Hu, Y., Davies, G. E. (2010). Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia, 81(5), 358-366.
Hu, Y., Ehli, E. A., Kittelsrud, J., Ronan, P. J., Munger, K., Downey, T., Bohlen, K., Callahan, L., Munson, V., Jahnke, M., Marshall, L. L., Nelson, K., Huizenga, P., Hansen, R., Soundy, T. J., Davies, G. E. (2012). Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine, 19(10), 861–867.
Landi, F., Martone, A. M., Salini, S., Zazzara, B., Calvani, R., Marzetti, E., Nesci, A., Giorgio, A., Giupponi, B., Santoro, L. (2019). Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: a pilot randomized trial. Biomed Research International, 2019, 1-7.
León-Martínez, J. M., Martínez-Abundis, E., González-Ortiz, M., & Pérez-Rubio, K. G. (2020). Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: a pilot clinical trial. Journal of Medicinal Food, 00(0), 1–5.
Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., Rosano, G. (2011). Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Advances in Therapy, 28(12), 1105–1113.
Pierro F. (2016). Berberina. Topics on Biopharmaceutical Phytotherapy. Cec Editore. Italia.
Pierro, F., Putignano, P., Ferrara, T., Raiola, C., Rapacioli, G., Villanova, N. (2017). Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia. Clinical Pharmacology: Advances and Applications, 9, 1-7.
Souza, C.D.; Felfili, J.M. (2006). Uso de plantas medicinais na região de Alto Paraíso de Goiás, GO, Brasil. Acta Botânica Brasileira, 20(1), 135-142.
Santos, R. L., Guimaraes, G. P., Nobre, M. S. C. & Portela, A. S. (2011). Análise sobre a fitoterapia como prática integrativa no Sistema Único de Saúde. Revista brasileira de plantas medicinais, 13(4), 486-491.
Spigoni, V., Aldigeri, R., Antonini, M., Micheli, M., Fantuzzi, F., Fratter, A., Pellizzato, M., Derlindati, E., Zavaroni, I., Bonadonna, R. (2017). Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: results from a randomized, double blind, placebo-controlled study. International Journal of Molecular Sciences, 18(7), 1-15.
Trimarco, V., Izzo, R., Stabile, E., Rozza, F., Santoro, M., Manzi, M. V., Serino, F., Schiattarella, G. G., Esposito, G., Trimarco, B. (2015). Effects of a New Combination of Nutraceuticals with Morus alba on Lipid Profile, Insulin Sensitivity and Endotelial Function in Dyslipidemic Subjects. A Cross-Over, Randomized, Double-Blind Trial. High Blood Pressure & Cardiovascular Prevention, 22(2), 149-154.
Veiga-Junior, V. F. (2008). Estudo do consumo de plantas medicinais na Região Centro-Norte do Estado do Rio de Janeiro: aceitação pelos profissionais de saúde e modo de uso pela população. Revista Brasileira de Farmacognosia, 18(2), 308-313.
Vuddanda, P. R., Chakraborty, S., Singh, S. (2010). Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opinion On Investigational Drugs, 19(10), 1297-1307.
Wilkinson, M. J., Laffin, L. J., Davidson, M. H. (2014). Superando a toxicidade e os efeitos colaterais das terapias hipolipemiantes. Best Practice & Research Clinical Endocrinology & Metabolism, 28, 439–452.
Wei, W., Zhao, H., Wang, A., Sui, M., Liang, k., Deng, H., Ma, Y., Zhang, Y., Zhang, H., Guan, Y. (2012). A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European Journal of Endocrinology, 166(1), 99-105.
Yang, J., Yin, J., Gao, H., Xu, L., Wang, Y., Xu, L., Li, M. (2012). Berberine Improves Insulin Sensitivity by Inhibiting Fat Store and Adjusting Adipokines Profile in Human Preadipocytes and Metabolic Syndrome Patients. Evidence-Based. Complementary and Alternative Medicine, 2012, 1-9.
Zhang, H., Temel, R. E., Martel, C. (2014). Cholesterol and Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(9), 1791-1794.
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., Ren, G., Ning, G. (2008). Treatment of Type 2Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine. The Journal of Clinical Endocrinology & Metabolism, 93(7), 2559-2565.
How to Cite
Copyright (c) 2021 Débora Martins Cavalheiro; Keylla de Araújo Silva; Bruna Emanuele Pereira Cardoso; Thaline Milany da Silva Dias; Alana Rafaela da Silva Moura; Stéfany Rodrigues de Sousa Melo; Maiara Jaianne Bezerra Leal Rios; Jennifer Beatriz Silva Morais
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.